Form 4: Agios Pharmaceuticals Director Rahul Ballal Reports Stock Unit Vesting
SEC Form 4 Filing
Director Rahul Ballal reports vesting of restricted stock units into common stock of Agios Pharmaceuticals.
Summary
- On June 13, 2024, Rahul Ballal, a director of Agios Pharmaceuticals, had restricted stock units vest into 3,388 shares of common stock.
- These restricted stock units were initially granted on June 13, 2023, and vested in full on June 13, 2024.
- Following the transaction, Ballal directly owns 5,690 shares of Agios Pharmaceuticals common stock.
- The vested shares will be delivered to Ballal within three business days.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of a scheduled vesting event.
Positives
- The vesting of restricted stock units indicates confidence in the company's future performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 06/13/2023 | Restricted stock units were granted. |
| 06/13/2024 | Restricted stock units vested into common stock. |
| 06/17/2024 | Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.